0000000000803589

AUTHOR

H.-j. Lück

showing 2 related works from this author

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program o…

2013

BACKGROUND Compliance and persistence are often overlooked in adjuvant breast cancer treatment. PATIENTS AND METHODS PACT was a prospective, multicenter, randomized, open, parallel-group study assessing whether educational materials (EMs) enhanced compliance with aromatase inhibitor (AI) therapy in postmenopausal women with early, hormone-receptor-positive (HR+) breast cancer. The primary end points were compliance (proportion taking ≥ 80% anastrozole) at 12 months and persistence (proportion reporting anastrozole intake during the study period). RESULTS Four thousand eight hundred and forty-four patients were randomly assigned 1:1 to receive standard therapy or standard therapy with EMs. T…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classmedicine.medical_treatmentAnastrozoleBreast NeoplasmsAnastrozolePactPersistence (computer science)Medication AdherenceEosinophilia–myalgia syndromeBreast cancerInternal medicineNitrilesmedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyAromatase inhibitorbusiness.industrySurrogate endpointHematologyMiddle AgedTriazolesmedicine.diseasePostmenopauseOncologyPatient ComplianceFemalebusinessAdjuvantmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Supplementary Material for: Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impac…

2019

Background: Breast cancer patients’ self-understanding of their disease can impact their quality of life (QoL); the relationship between compliance and QoL is poorly understood. Patients and Methods: The Patient’s Anastrozole Compliance to Therapy (PACT) program, a prospective, randomized study, investigated the effect of additional patient information material (IM) packages on compliance with adjuvant aromatase inhibitor (AI) therapy in postmenopausal women with hormone receptor-positive early breast cancer. The QoL subanalysis presented here examined the impact of IM packages on QoL and the association between QoL and compliance. European Organization for Research and Treatment of Cancer …

humanities
researchProduct